A Single Ascending Dose and Multiple Ascending Dose Phase I Study of PXS-5382A Administered Orally in Healthy Male Adult Volunteers

Trial Profile

A Single Ascending Dose and Multiple Ascending Dose Phase I Study of PXS-5382A Administered Orally in Healthy Male Adult Volunteers

Recruiting
Phase of Trial: Phase I

Latest Information Update: 27 Nov 2017

At a glance

  • Drugs PXS-5382A (Primary)
  • Indications Idiopathic pulmonary fibrosis; Non-alcoholic steatohepatitis; Pulmonary fibrosis; Renal fibrosis
  • Focus Adverse reactions
  • Sponsors Synairgen
  • Most Recent Events

    • 24 Nov 2017 Status changed from planning to recruiting.
    • 06 Sep 2017 Planned initiation date changed from 1 Jan 2017 to 1 Oct 2017 as per the Synairgen media release.
    • 06 Sep 2017 According to the Synairgen media release, the company will commense phase I trial in Q4 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top